US OptionsDetailed Quotes

NAMS250516C25000

Watchlist

3.30
0.000.00%

15min DelayClose May 5 16:00 ET

0.00High0.00Low

NewAmsterdam Pharma Stock Discussion

Teddy123

Apr 30 20:09

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

$NewAmsterdam Pharma (NAMS.US)$
Major Breakthrough: NewAmsterdam Reveals Multiple Phase 3 Trial Results for Novel Heart Drug

10xStockPicks

Feb 21 21:57

Esperion Therapeutics On The Verge Of Being Acquired, Upside Could Be Over 500% In The Near Future

$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR): A High-Growth Opportunity with Potential 10x Returns
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...

10xStockPicks

Dec 16, 2024 08:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 16, 2024 05:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

103848509

Dec 10, 2024 21:21

$NewAmsterdam Pharma (NAMS.US)$ niceerr high fly prolly

Jaguar8

Nov 20, 2024 22:16

NEWS

$NewAmsterdam Pharma (NAMS.US)$
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significa...

SteadyBoomBeepBeep

Nov 20, 2024 20:18

$NewAmsterdam Pharma (NAMS.US)$ on watch

⭕北美深蓝

Jul 30, 2024 16:54

⛔本次下跌合理吗？

$NewAmsterdam Pharma (NAMS.US)$ ⭕NewAmsterdam Pharma（NAMS）周一表示，对于家族性高胆固醇血症杂合子患者潜在降低胆固醇的药物obicetrapib的3期临床研究已达到主要终点，但是，股价却在消息发布后跌超8%，为此，找到相关本次临床相关信息以便进一步评估其下跌：
🔺obicetrapib是用于治疗低密度脂蛋白胆固醇（“LDL-C”）升高且有心血管疾病（“CVD”）风险的患者，这些患者现有疗法效果不够好或耐受性不佳
🔺本次临床试验的对象及其入选条件
Study Overview
Brief Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hyper...

Meltyy

May 16, 2024 14:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Moomoo AI

Mar 3, 2024 20:36

Analysts have upgraded revenue forecasts for NewAmsterdam Pharma next year, despite slower expected growth than the industry. They also increased the price target, indicating an improved intrinsic business value.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

No comment yet